Springe direkt zu Inhalt

Wahlpflichtfach

Angebotene Themen

Forschungsverbünde deutscher Hochschulen auf dem Gebiet der Klinischen Pharmazie [FoKP2-I]

Klinische Pharmazie, das jüngste der fünf pharmazeutischen Kernfächer, ist nach wie vor nicht an allen Hochschulstandorten durch einen forschenden Arbeitskreis vertreten. Dennoch sind die Forschungsprojekte im Fach Klinische Pharmazie meist sehr interdisziplinär angelegt und die Partner zu größeren Verbünden zusammengeschlossen. Ziel der Arbeit ist, 17 Jahre nach Eingang des Fachs Klinische Pharmazie in die Approbationsordnung für Apotheker und 4 Jahre nach der ersten im AK Kloft durchgeführten bundesweiten Erhebung zu größeren Forschungskooperationen/Forschungsverbünden im Fach Klinische Pharmazie, eine erneute Bilanz zur Forschungsaktivität des Faches zu ziehen. Veränderungen und Entwicklungen im Vergleich zur letzten Erhebung sollen zusammengetragen und damit der wissenschaftliche Beitrag des Faches neu bewertet werden. Nach Abschluss der Pilotphase sollen in der Hauptphase die Untersuchung mittels online-Fragebogen durchgeführt und ggf., je nach zeitlicher Kapazität, die gewonnenen Daten ausgewertet werden.

Weitere Informationen: FoKP2-I


Literaturgestützter Vergleich der analysemethoden klinischer Mikrodialysedaten [INF_µD]

Microdialysis is a minimally invasive method to obtain drug concentrations at target site in virtually any tissue. However, analysis of such data is not trivial and there is no consensus on what methodology to employ. In a systematic review of available literature the aims of this analysis are:

  1. Overview of clinical studies including the microdialysis technique categorised by the employed analysis method.

  2. Comparison of outcomes with respect to pharmacokinetic parameters and their variability between the different analysis approaches.

Weitere Informationen: INF_µD


Literature Research: Physiologically based pharmacokinetic modelling of Infiximab in bowel diseases. [INFLIX]

Over the past few decades, monoclonal antibodies (mAbs) have become one of the most important and fastest growing classes of therapeutic molecules, with applications in a wide variety of disease areas such inflammatory bowel diseases (IBD). However, their pharmacological (pharmacokinetic and pharmacodynamic) properties differ substantially from small molecule drugs. In this context, physiologically-based pharmacokinetic (PBPK) models are an interesting approach to characterise the different pharmacokinetic processes of these mAbs. Here, we will focus on infliximab, an anti-TNFα mAb indicated in the treatment of patients with moderate to severe IBD.

Further information: INFLIX


Effect of liver transplantation on CYP3A activity [LIVER]

Cytochrome P450 plays an important role in the metabolism of several drugs. The most abundant isoform is CYP3A which is responsible for the metabolism of more than 50% of drugs. CYP3A is mainly present in the liver and intestine. Like with other enzymes, hepatic CYP3A activity is greatly affected by the physiological status of the liver e.g. hepatic circulation, presence/absence of inflammation, aging, etc. Liver damage and the necessity of liver transplantation is of no exception. The project aims to identify the changes in hepatic CYP3A activity encountered as a result of the latter procedure. Will extrahepatic CYP3A become overexpressed and take over? Will the lag time between liver transplant and restoration of blood flow affect the restored hepatic CYP3A activity? A case example, from the literature, on one of the CYP3A substrates’ fate before and after liver transplant is also encouraged.

Further information: LIVER

.

Role of Biomarkers (Carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) in non-small cell lung cancer (NSCLC) [Biomark]

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. Early diagnosis is usually difficult due to the absence of clinical symptoms. In addition, monitoring response has been restricted to imaging techniques that hardly capture unmeasurable disease. Therefore, more surrogate measures are needed for both diagnosis and disease/treatment monitoring. Biomarkers, among which carcinoembryonic antigen (CEA) and cytokeratin-19 fragments(CYFRA21-1), have been potential surrogates with increasing and debatable interpretations on their screening, diagnostic, monitoring, predictive and prognostic capabilities.

This project aims to assess the various potential roles of both CEA and CYFRA21-1 in NSCLC through an extensive literature review with emphasis on areas with greatest potential for future research.

Further information: BIOMARK

.

Literature Research: Pharmacokinetic/pharmacodynamic of Anti-TNF (focus on Infiximab) in inflammatory bowel diseases [Anti-TNF]

Therapeutic monoclonal antibodies (mAbs) against the cytokine TNFα are a standard treatment for patients with moderate to severe inflammatory bowel diseases (IBD). The understanding of the pharmacokinetic/pharmacodynamic (PK/PD) relationship of those compounds is essential to adapt the dosing regimen to the patients and optimise therapy.

Further information: Anti-TNF



Hinweise zur Bewerbung für das Wahlpflichtfach

Aktueller Bewerbungsschluss: